These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31736377)

  • 1. Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.
    Tužil J; Mlčoch T; Jirčíková J; Závada J; Nekvindová L; Svoboda M; Uher M; Křístková Z; Vencovský J; Pavelka K; Doležal T
    Expert Opin Biol Ther; 2020 Feb; 20(2):183-192. PubMed ID: 31736377
    [No Abstract]   [Full Text] [Related]  

  • 2. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
    Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
    BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy.
    Vastesaeger N; Cruyssen BV; Mulero J; Gratacós Masmitjá J; Zarco P; Almodovar R; Font P; Juanola X; Collantes-Estevez E;
    Reumatol Clin; 2014; 10(4):204-9. PubMed ID: 24598027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.
    Salaffi F; Ciapetti A; Carotti M; Gasparini S; Citera G; Gutierrez M
    Health Qual Life Outcomes; 2014 Aug; 12():129. PubMed ID: 25146299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
    Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.
    Kwan YH; Tan JJ; Phang JK; Fong W; Lim KK; Koh HL; Lui NL; Tan CS; Østbye T; Thumboo J; Leung YY
    Int J Rheum Dis; 2019 Dec; 22(12):2206-2212. PubMed ID: 31721427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis.
    Aydin SZ; Can M; Atagunduz P; Direskeneli H
    Clin Exp Rheumatol; 2010; 28(5):752-5. PubMed ID: 20863448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy.
    Prince DS; McGuigan LE; McGirr EE
    Int J Rheum Dis; 2014 Feb; 17(2):165-72. PubMed ID: 24576272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors.
    Shimabuco AY; Gonçalves CR; Moraes JCB; Waisberg MG; Ribeiro ACM; Sampaio-Barros PD; Goldenstein-Schainberg C; Bonfa E; Saad CGS
    Adv Rheumatol; 2018 Dec; 58(1):40. PubMed ID: 30657103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA.
    Pavelka K; Forejtová S; Stolfa J; Chroust K; Buresová L; Mann H; Vencovský J
    Clin Exp Rheumatol; 2009; 27(6):958-63. PubMed ID: 20149312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.
    Monti S; Todoerti M; Codullo V; Favalli EG; Biggioggero M; Becciolini A; Montecucco C; Caporali R
    Mod Rheumatol; 2018 May; 28(3):542-549. PubMed ID: 28880727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
    Ramiro S; van der Heijde D; van Tubergen A; Stolwijk C; Dougados M; van den Bosch F; Landewé R
    Ann Rheum Dis; 2014 Aug; 73(8):1455-61. PubMed ID: 24812292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Scoring of disease activity using BASDAI and ASDAS method in ankylosing spondylitis].
    Bobek D; Zagar I; Kovač-Durmiš K; Perić P; Ćurković B; Babić-Naglić Ð
    Reumatizam; 2012; 59(1):5-10. PubMed ID: 25486721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.
    Závada J; Uher M; Sisol K; Forejtová Š; Jarošová K; Mann H; Vencovský J; Pavelka K
    Ann Rheum Dis; 2016 Jan; 75(1):96-102. PubMed ID: 25165033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
    Xu M; Lin Z; Deng X; Li L; Wei Y; Liao Z; Li Q; Wei Q; Hu Z; Zhang Y; Lin Q; Huang J; Li T; Pan Y; Wu Y; Jin O; Yu B; Gu J
    Rheumatology (Oxford); 2011 Aug; 50(8):1466-72. PubMed ID: 21441550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study.
    Michielsens C; Bolhuis TE; van Gaalen FA; van den Hoogen F; Verhoef LM; den Broeder N; den Broeder AA
    Scand J Rheumatol; 2024 May; 53(3):180-187. PubMed ID: 37339375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.